Recherche

Afficher tous les résultats pour

Accueil

Personne

Patrick Aebischer

Publications associées (172)

À propos
Confidentialité
Mentions légales

Graph Chatbot

How to build science capacity

Patrick Aebischer

Nature Publishing Group2012

Use of viral vectors to create animal models for Parkinson's disease

Patrick Aebischer

Parkinson's disease is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra. While sporadic in the majority of cases. PD-linked dominant mutations in the a-synuclein and LRRK-2 genes, and recess ...

Elsevier2012

System and Method For In Vivo Delivery of Antibodies and Fragments Thereof

Patrick Aebischer, Maurizio Molinari, Nicolas Bouche

The present invention is directed to devices and methods for in situ delivering an antibody or a fragment thereof to a host. In particular, the invention relates to devices and methods for in situ delivering an antibody or a fragment thereof to patient suf ...

2011

Chronic delivery of antibody fragments using immunoisolated cell implants as a passive vaccination tool

Rolf Gruetter, Maria del Carmen Sandi Perez, Patrick Aebischer, Jean-Charles Bensadoun, Maurizio Molinari, Nicolas Bouche, Maria Isabel Cordero Campana, Veronica Setola, Osiris Marroquin Belaunzaran

BACKGROUND: Monoclonal antibodies and antibody fragments are powerful biotherapeutics for various debilitating diseases. However, high production costs, functional limitations such as inadequate pharmacokinetics and tissue accessibility are the current pri ...

Public Library of Science2011

Proton and phosphorus MRS of a 5xFAD mouse model of Alzheimer's disease

Rolf Gruetter, Patrick Aebischer, Bernard Schneider, Hongxia Lei, Sharon Janssens, Lili Sun-Reimer

2011

Use of igf-1 and nt-3 in the treatment of x-linked adrenoleukodystrophy

Patrick Aebischer, Jean-Charles Bensadoun

The present invention is directed to new compositions uses thereof and related methods for the treatment of X- linked adrenoleukodystrophy. ...

2010

Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions

Hilal Lashuel, Patrick Aebischer, Bernard Schneider, Adrian Schmid, Diego Chiappe, Abid Oueslati, Marc Moniatte, Magdalena Zweckstetter

Increasing evidence suggests that phosphorylation may play an important role in the oligomerization, fibrillogenesis, Lewy body (LB) formation, and neurotoxicity of alpha-synuclein (alpha-syn) in Parkinson disease. Herein we demonstrate that alpha-syn is p ...

2010

Neurodegenerative Disorders: Gene Therapy on Clinical Trial

Patrick Aebischer

Frontiers Research Foundation2010

Neuroprotection by Gene Therapy Targeting Mutant SOD1 in Individual Pools of Motor Neurons Does not Translate Into Therapeutic Benefit in fALS Mice

Patrick Aebischer, Bernard Schneider, Veronica Setola, Christopher Towne

A major challenge in neurological gene therapy is delivery of the transgene to sufficient cell numbers in an atraumatic manner. This is particularly difficult for motor neuron (MN) diseases that have cells located across the entire spinal cord, brain stem, ...

Elsevier2010

Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6

Patrick Aebischer, Bernard Schneider, Christopher Towne

Retrograde transport of viral vectors in the rodent spinal cord provides a powerful means to administer a therapeutic transgene from the innervated musculature. With the aim of scaling up this approach to non-human primates, we have injected recombinant ad ...

2010

Page 4 sur 18

2010

Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions

Hilal Lashuel, Patrick Aebischer, Bernard Schneider, Adrian Schmid, Diego Chiappe, Abid Oueslati, Marc Moniatte, Magdalena Zweckstetter

2010

Neurodegenerative Disorders: Gene Therapy on Clinical Trial

Patrick Aebischer

Frontiers Research Foundation2010

Neuroprotection by Gene Therapy Targeting Mutant SOD1 in Individual Pools of Motor Neurons Does not Translate Into Therapeutic Benefit in fALS Mice

Patrick Aebischer, Bernard Schneider, Veronica Setola, Christopher Towne

Elsevier2010

Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6

Patrick Aebischer, Bernard Schneider, Christopher Towne

2010

System and Method For In Vivo Delivery of Antibodies and Fragments Thereof

Patrick Aebischer, Maurizio Molinari, Nicolas Bouche

2011